Compound · clinical trials

Vincristine clinical trials

Also listed in trial records as Oncovin, Vincristine Sulfate, Leurocristine, Kyocristine, Sulfate, Vincasar, Vincosid, Vincrex, L01CA02, VP16, carboplatin, vincristin, Oncovin(R)

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 121 trials in our Canada, Australia, Israel, China, France, Mexico, Spain, Italy, Germany, Austria, USA, Poland, Czechia, Belgium, Netherlands, South Korea, Taiwan, Turkey, Japan, Brazil, Denmark, UK, Switzerland, Sweden, Portugal, Ireland, Norway, Singapore, India and Egypt registers that name Vincristine as an intervention. Synced 9 Nov 2026

121Current trials

55Recruiting now

58Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Vincristine is named as an intervention in 121 current clinical trials in our Canada, Australia, Israel, China, France, Mexico, Spain, Italy, Germany, Austria, USA, Poland, Czechia, Belgium, Netherlands, South Korea, Taiwan, Turkey, Japan, Brazil, Denmark, UK, Switzerland, Sweden, Portugal, Ireland, Norway, Singapore, India and Egypt registers. 55 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (20). The most-studied condition is Acute Lymphoblastic Leukemia. The EU clinical trials register (CTIS) separately lists 5 authorised or ongoing trials, 1 with a site in Ireland.

Where Vincristine is approved

All regulators →

Of the three regulators tracked here, the first to approve Vincristine was the US, on 10 Jul 1963. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)

10 Jul 1963

Oncovin

NDA014103 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

25 Nov 1994

Vincristine Sulphate Injection

Notice of Compliance 5628

First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Vincristine

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$165k

11,058 prescriptions in 2025 · VinCRIStine Sulfate

-54% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Vincristine works

All drug targets →

Tubulin inhibitor Inhibitor
Target: Tubulin
✓ In ChEMBL and the Guide to Pharmacology

Diseases it has been tested for in clinical trials, by furthest phase

AIDSPhase 3
B-cell acute lymphoblastic leukemiaPhase 3
B-cell chronic lymphocytic leukemiaPhase 3
Burkitt lymphomaPhase 3
Ewing sarcomaPhase 3
Hodgkins lymphomaPhase 3
Kaposi's sarcomaPhase 3
Langerhans cell histiocytosisPhase 3
NephroblastomaPhase 3
Richter transformationPhase 3

130 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL90555, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6785, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Vincristine

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 1 product on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Vincristine

ATC code: L01CA02
ChEMBL: CHEMBL90555
DrugBank: DB00541
PubChem CID: 5978
CAS number: 57-22-7
FDA UNII: 5J49Q6B70F
Wikidata: Q408977
Wikipedia: Vincristine

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting5545%
Not yet open97%
Active, closed5646%
By invitation11%

Trials by phase

Phase 35041%
Phase 23731%
Phase 1/21311%
Phase 2/397%
Phase 154%
Not applicable22%
Phase 422%
Observational22%
Early Phase 111%

Clinical trials of Vincristine

121 trials

Study	Phase	Status	Lead sponsor	Registers
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) NCT03126916 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Israel
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia NCT03150693 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Canada, Mexico, Israel
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 NCT03643276 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Recruiting	Martin Schrappe	Germany, Italy, Switzerland, Austria, Czechia, Australia, Israel
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy NCT03959085 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma NCT04043494 · Lymphoblastic Lymphoma, Childhood	Phase 3	Recruiting	University Hospital Muenster	Ireland, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Israel
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma NCT04166409 · ClinicalTrials.gov ↗ · Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) NCT04221035 · ClinicalTrials.gov ↗ · High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Australia, Israel
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) NCT04638790 · Hodgkin Lymphoma, Adult	Phase 3	Recruiting	State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia	India
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma NCT05304585 · ClinicalTrials.gov ↗ · Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss NCT05382338 · Childhood Medulloblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Israel
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab NCT05675410 · ClinicalTrials.gov ↗ · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma NCT06091254 · Follicular Lymphoma (FL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma NCT06091865 · Diffuse Large B-cell Lymphoma (DLBCL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma NCT06172296 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma NCT06220032 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma	Phase 3	Recruiting	Stichting Hemato-Oncologie voor Volwassenen Nederland	Netherlands
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) NCT06401330 · Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor	Phase 3	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma NCT06647953 · ClinicalTrials.gov ↗ · Pleuropulmonary Blastoma	Phase 3	Recruiting	Children's Oncology Group	Canada
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) NCT06717347 · Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	USA, China, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) NCT06911502 · Follicular Lymphoma	Phase 3	Recruiting	Celgene	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Japan, South Korea, Australia
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol NCT07152041 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic	Phase 3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) NCT07466316 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma	Phase 3	Recruiting	Children's Oncology Group	Canada
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma NCT02265770 · Childhood Ependymoma	Phase 2/3	Recruiting	Centre Leon Berard	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol NCT06764238 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)	Phase 2/3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Newly-diagnosed Pediatric T-cell ALL Protocol NCT06855810 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma	Phase 2/3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol NCT06882057 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)	Phase 2/3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) NCT07634471 · Follicular Lymphoma	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	USA, China, Spain, Italy, Poland, Turkey, South Korea, Taiwan, Australia, Israel
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT NCT04322318 · ClinicalTrials.gov ↗ · Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor	Phase 2	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage NCT04440267 · ClinicalTrials.gov ↗ · Acute Leukemia of Ambiguous Lineage	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT04546399 · ClinicalTrials.gov ↗ · Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma NCT04922567 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma, Lenalidomide, CHOP	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study NCT05457829 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma, Child	Phase 2	Recruiting	Sun Yat-sen University	China
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma NCT05504291 · ClinicalTrials.gov ↗ · Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma	Phase 2	Recruiting	Children's Oncology Group	Canada, Australia
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia NCT05660473 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia NCT06034561 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission	Phase 2	Recruiting	Instituto do Cancer do Estado de São Paulo	Brazil
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT06124157 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia
Ma-Spore ALL 2020 Study NCT06336395 · ClinicalTrials.gov ↗ · B Lymphoblastic Leukemia	Phase 2	Recruiting	National University Hospital, Singapore	Singapore
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL NCT06387121 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. NCT06514313 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma	Phase 2	Recruiting	Yizhuo Zhang	China
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial NCT06700798 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL)	Phase 2	Recruiting	Fei Li	China
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma NCT06704555 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL NCT07493148 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Recruiting	Ou Bai, MD/PHD	China
A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation NCT07917780 · Richter Transformation	Phase 2	Recruiting	German CLL Study Group	Ireland, Germany, Denmark, Austria, Australia
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 · ClinicalTrials.gov ↗ · DLBCL, Untreated, MYC Gene Rearrangement	Phase 1/2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma NCT04625907 · Rhabdomyosarcoma	Phase 1/2	Recruiting	University of Birmingham	Ireland, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Portugal, Australia, Israel
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) NCT05384821 · ClinicalTrials.gov ↗ · Wilms Tumor	Phase 1/2	Recruiting	Centre Oscar Lambret	France
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors NCT06541262 · ClinicalTrials.gov ↗ · Neuroblastoma, Ewing Sarcoma, Osteosarcoma	Phase 1/2	Recruiting	Milton S. Hershey Medical Center	Canada
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Denmark, Czechia, Japan, South Korea, Taiwan, Australia
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) NCT07387926 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Phase 1/2	Recruiting	Novartis Pharmaceuticals	South Korea, Taiwan, Australia, Israel
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 · ClinicalTrials.gov ↗ · Hematologic Malignancy, AML, ALL	Phase 1	Recruiting	Therapeutic Advances in Childhood Leukemia Consortium	Australia
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors NCT06760117 · ClinicalTrials.gov ↗ · Pediatric Solid Tumor	Phase 1	Recruiting	Sun Yat-sen University	China
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies NCT07308132 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin	Phase 1	Recruiting	Janssen Research & Development, LLC	France, Spain, Belgium, Turkey, Australia
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL NCT05899621 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Observational	Recruiting	Ruijin Hospital	China
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents NCT02797717 · ClinicalTrials.gov ↗ · Classical Hodgkins Lymphoma in Children and Adolescents.	Not applicable	Recruiting	GALIA AVRAHAMI	Israel
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis NCT07431060 · ClinicalTrials.gov ↗ · Langerhans Cell Histiocytosis (LCH)	Not applicable	Recruiting	West China Second University Hospital	China
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation NCT06942039 · ClinicalTrials.gov ↗ · CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor	Early Phase 1	Recruiting	C17 Council	Canada
Combination Therapy of Anthracyclines for Children With Nephroblastoma NCT03892330 · ClinicalTrials.gov ↗ · 0.5-14 Year Old Children With Nephroblastoma	Phase 4	Not yet open	Shengjing Hospital	China
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma NCT07719855 · ClinicalTrials.gov ↗ · Follicular Lymphoma ( FL)	Phase 3	Not yet open	Ruijin Hospital	China
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) NCT07712588 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2/3	Not yet open	Dizal Pharmaceuticals	China
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients NCT07301138 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 2	Not yet open	Ruijin Hospital	China
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma NCT07535762 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)	Phase 2	Not yet open	Shanghai Jiao Tong University School of Medicine	China
The CARDIOPROTECT Trial NCT07654426 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma	Phase 2	Not yet open	Beth Israel Deaconess Medical Center	Israel
A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) NCT07676175 · ClinicalTrials.gov ↗ · Previously Untreated Peripheral T-Cell Lymphoma	Phase 2	Not yet open	BeBetter Med Inc	China
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma NCT07535710 · ClinicalTrials.gov ↗ · Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome	Phase 1/2	Not yet open	Shanghai Jiao Tong University School of Medicine	China
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma NCT07818499 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 1/2	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH NCT05678933 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma Targeted Therapy	Phase 3	By invitation	Tianjin Medical University Cancer Institute and Hospital	China
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors NCT02875314 · ClinicalTrials.gov ↗ · Medulloblastoma, Central Nervous System Embryonal Tumors	Phase 4	Active, closed	Parth Patel	Canada
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease NCT00002462 · ClinicalTrials.gov ↗ · Lymphoma	Phase 3	Active, closed	European Organisation for Research and Treatment of Cancer - EORTC	Germany, France, Italy, Netherlands, Belgium, Poland, Portugal, Egypt
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma NCT00887146 · ClinicalTrials.gov ↗ · Brain and Central Nervous System Tumors	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	France, Netherlands, Belgium, Austria, Canada, Mexico
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia NCT02003222 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia NCT02101853 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia, Israel
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma NCT02112916 · ClinicalTrials.gov ↗ · Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma NCT02166463 · ClinicalTrials.gov ↗ · Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma NCT02306161 · ClinicalTrials.gov ↗ · Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma NCT02567435 · ClinicalTrials.gov ↗ · Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia, Israel
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT03007147 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia	Phase 3	Active, closed	Children's Oncology Group	Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Canada, Mexico, Australia, Israel
Paediatric Hepatic International Tumour Trial NCT03017326 · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland, Germany, France, Spain, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Israel
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents NCT03020030 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Active, closed	Dana-Farber Cancer Institute	Canada
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents NCT03206671 · Mature B-cell Non-Hodgkin Lymphoma	Phase 3	Active, closed	University Hospital Muenster	Germany, Sweden, Denmark, Switzerland, Austria, Czechia, Norway
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia NCT03589326 · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	Phase 3	Active, closed	Takeda	USA, China, France, Spain, Italy, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma NCT03871257 · ClinicalTrials.gov ↗ · Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia NCT03914625 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) NCT04529772 · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Acerta Pharma BV	USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults NCT04530565 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma NCT04759586 · ClinicalTrials.gov ↗ · Primary Mediastinal Large B-Cell Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients NCT04824092 · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Incyte Corporation	Ireland, UK, USA, Germany, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma NCT04994132 · ClinicalTrials.gov ↗ · Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Australia, Israel
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma NCT05371093 · Relapsed/Refractory Follicular Lymphoma	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA, Germany, France, Spain, Italy, Japan
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) NCT05578976 · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Genmab	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma NCT05605899 · High-risk Large B-cell Lymphoma (LBCL)	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA, Germany, France, Spain, Italy, Netherlands, Austria, Portugal, Canada, Japan, Australia
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma NCT06097364 · Follicular Lymphoma (FL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Turkey, Brazil, Taiwan, Australia, Israel
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma NCT06191744 · Follicular Lymphoma (FL)	Phase 3	Active, closed	Genmab	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma NCT06356129 · Large B-cell Lymphoma	Phase 3	Active, closed	Celgene	USA, India, China, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma NCT03117751 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma	Phase 2/3	Active, closed	St. Jude Children's Research Hospital	Australia
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas NCT03984448 · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma NCT04799275 · ClinicalTrials.gov ↗ · Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Israel
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma NCT01856192 · ClinicalTrials.gov ↗ · Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma NCT01878617 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Active, closed	St. Jude Children's Research Hospital	Canada, Australia
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia NCT02143414 · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer NCT02299999 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Active, closed	UNICANCER	France
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma NCT02724579 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Active, closed	Children's Oncology Group	Canada, Australia, Israel
Conservative Treatments of Retinoblastoma NCT02866136 · ClinicalTrials.gov ↗ · Retinoblastoma, Children, Retinal Neoplasm	Phase 2	Active, closed	Institut Curie	France
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) NCT02870907 · ClinicalTrials.gov ↗ · Retinoblastoma	Phase 2	Active, closed	Institut Curie	France
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia NCT02981628 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia	Phase 2	Active, closed	Children's Oncology Group	Israel
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma NCT03269669 · ClinicalTrials.gov ↗ · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 NCT03286634 · Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer	Phase 2	Active, closed	National Hospital Organization Nagoya Medical Center	Japan, Taiwan, Singapore
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) NCT03407144 · Hodgkin Lymphoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Brazil, Mexico, South Korea
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma NCT04067037 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma	Phase 2	Active, closed	Henan Cancer Hospital	China
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma NCT04980222 · Lymphoma	Phase 2	Active, closed	Hoffmann-La Roche	USA, France, Spain, Netherlands, Denmark, Poland
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia NCT05303792 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma	Phase 2	Active, closed	Alliance for Clinical Trials in Oncology	Mexico
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia NCT05761171 · ClinicalTrials.gov ↗ · Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage	Phase 2	Active, closed	Children's Oncology Group	Canada, Mexico, Israel
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma NCT06425302 · Lymphoma, Follicular	Phase 2	Active, closed	Celgene	UK, USA, Germany, France, Spain, Italy, Poland, Canada, Brazil, South Korea, Taiwan, Australia
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL NCT07480863 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL)	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I NCT02553460 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 1/2	Active, closed	St. Jude Children's Research Hospital	Canada
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy NCT02889523 · ClinicalTrials.gov ↗ · Lymphoma, DLBCL, Follicular Lymphoma	Phase 1/2	Active, closed	The Lymphoma Academic Research Organisation	France, Belgium
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia NCT03504644 · ClinicalTrials.gov ↗ · Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma	Phase 1/2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma NCT03817320 · ClinicalTrials.gov ↗ · ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood	Phase 1/2	Active, closed	Therapeutic Advances in Childhood Leukemia Consortium	Australia
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma NCT05201248 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma	Phase 1/2	Active, closed	Genmab	China
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma NCT04884035 · Lymphoma, B-Cell	Phase 1	Active, closed	Celgene	USA, Spain, Poland, South Korea, Taiwan, Australia
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL NCT06541665 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
Vincristine Pharmacokinetics in Infants NCT05359237 · ClinicalTrials.gov ↗ · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm	Observational	Active, closed	Children's Oncology Group	Canada, Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Vincristine in the EU trials register (CTIS)

5 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Vincristine. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2 2024-513445-37-00 · Neoplasms	Phase 3	Ongoing	University Of Cologne	Ireland + 5 more
"EURbG2": A European prospective study of patients with unilateral retinoblastoma requiring enucleation, either first-line or after neoadjuvant chemotherapy, with analysis of histological risk factors and biomarkers at baseline and during follow-up 2024-515962-15-00 · CTIS ↗ · Eye Diseases	Phase 2	Authorised	Institut Curie	France
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia 2025-522190-11-01 · Neoplasms	Phase 3	Authorised	Universitaetsklinikum Schleswig-Holstein AöR	Germany
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) 2025-522019-40-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Novartis Pharma AG	Italy, Spain, Germany + 4 more
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020 2023-509392-17-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 3	Ongoing	Charite Universitaetsmedizin Berlin KöR	Netherlands, Czechia, Italy + 9 more

Vincristine across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Vincristine on the HPRA medicines list.

Vincristine Sulfate 1mg/ml Solution for Injection or InfusionPfizer Healthcare Ireland Unlimited Company · PA0822/232/001 · Marketed

All 1 Irish product →

Supply shortages

No entry for Vincristine in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Vincristine

170 conditions

Acute Lymphoblastic Leukemia9B Acute Lymphoblastic Leukemia7Follicular Lymphoma5 Diffuse Large B-Cell Lymphoma5Rhabdomyosarcoma4Lymphoma4Childhood Leukemia, Acute Lymphoblastic4Recurrent B Acute Lymphoblastic Leukemia4Follicular Lymphoma (FL)3Down Syndrome3Embryonal Rhabdomyosarcoma3Neuroblastoma3

All 170 conditions

Condition (as registered)	Trials
Acute Lymphoblastic Leukemia	9
B Acute Lymphoblastic Leukemia	7
Follicular Lymphoma	5
Diffuse Large B-Cell Lymphoma	5
Rhabdomyosarcoma	4
Lymphoma	4
Childhood Leukemia, Acute Lymphoblastic	4
Recurrent B Acute Lymphoblastic Leukemia	4
Follicular Lymphoma (FL)	3
Down Syndrome	3
Embryonal Rhabdomyosarcoma	3
Neuroblastoma	3
B Lymphoblastic Lymphoma	3
Medulloblastoma	3
Diffuse Large B-cell Lymphoma (DLBCL)	2
Hepatoblastoma	2
Lymphoblastic Lymphoma, Childhood	2
Large B-cell Lymphoma	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma	2
Marginal Zone Lymphoma(MZL)	2
Acute Lymphoblastic Leukemia ALL	2
B Cell Acute Lymphoblastic Leukemia (B-ALL)	2
Diffuse Large B-Cell Lymphoma (DLBCL)	2
DLBCL	2
Mixed Phenotype Acute Leukemia	2
Acute Lymphoblastic Leukemia, Pediatric	2
Retinoblastoma	2
Alveolar Rhabdomyosarcoma	2
Botryoid-Type Embryonal Rhabdomyosarcoma	2
Ganglioneuroblastoma, Nodular	2
Low Grade Glioma	2
Recurrent Acute Lymphoblastic Leukemia	2
Recurrent B Lymphoblastic Lymphoma	2
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	2
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma	2
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	2
Richter Transformation	1
Diffuse Large B-cell Lymphoma	1
Carcinoma, Hepatocellular	1
Childhood Ependymoma	1
Relapsed/Refractory Follicular Lymphoma	1
High-risk Large B-cell Lymphoma (LBCL)	1
Hodgkin Lymphoma	1
Lymphoma, Follicular	1
Chronic Lymphocytic Leukaemia	1
Small Lymphocytic Lymphoma	1
Mantle-cell Lymphoma	1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	1
Lymphoma, B-Cell	1
Hodgkin Lymphoma, Adult	1
Peripheral T-Cell Lymphoma (PTCL NOS)	1
Nodal T-follicular Helper Cell Lymphoma	1
Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)	1
Pediatric Solid Tumor	1
Acute Leukemia of Ambiguous Lineage	1
Cutaneous T-Cell Lymphoma Refractory	1
Cutaneous T-Cell Lymphoma, Relapsed	1
Sezary Syndrome	1
Cutaneous T Cell Lymphoma (CTCL)	1
Langerhans Cell Histiocytosis (LCH)	1
B-Cell Non-Hodgkin Lymphoma	1
0.5-14 Year Old Children With Nephroblastoma	1
T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma	1
Rhabdomyosarcoma, Child	1
Untreated	1
MYC Gene Rearrangement	1
Follicular Lymphoma ( FL)	1
Peripheral T-Cell Lymphoma	1
Lenalidomide	1
CHOP	1
Peripheral T-cell Lymphoma Targeted Therapy	1
Soft Tissue Sarcoma	1
Classical Hodgkin Lymphoma	1
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)	1
Mature B-cell Non-Hodgkin Lymphoma	1
T Acute Lymphoblastic Leukemia	1
High-Risk Neuroblastoma	1
Patient With Insufficient Response Chemoimmunotherapy	1
Brain and Central Nervous System Tumors	1
Wilms Tumor	1
Metastatic Breast Cancer	1
Lymphoma, Non-Hodgkin	1
DLBCL - Diffuse Large B Cell Lymphoma	1
Metastatic Embryonal Rhabdomyosarcoma	1
Childhood Medulloblastoma	1
Anaplastic Kidney Wilms Tumor	1
Recurrent Kidney Wilms Tumor	1
Stage II Kidney Wilms Tumor	1
Stage III Kidney Wilms Tumor	1
Ganglioneuroblastoma	1
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1
CNS Embryonal Tumor	1
CNS, Medulloblastoma	1
Atypical Teratoid Rhabdoid Tumor	1
Medulloblastoma, Childhood	1
Primary Mediastinal Large B-Cell Lymphoma	1
Fusion-Negative Alveolar Rhabdomyosarcoma	1
Spindle Cell/Sclerosing Rhabdomyosarcoma	1
Low Grade Astrocytoma	1
Metastatic Low Grade Astrocytoma	1
Metastatic Low Grade Glioma	1
Metastatic Ewing Sarcoma	1
Metastatic Malignant Neoplasm in the Bone	1
Metastatic Malignant Neoplasm in the Bone Marrow	1
Metastatic Malignant Neoplasm in the Lung	1
Hematopoietic and Lymphoid Cell Neoplasm	1
Malignant Solid Neoplasm	1
Central Nervous System Leukemia	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Central Nervous System Embryonal Tumors	1
Neurofibromatosis Type 1	1
Visual Pathway Glioma	1
Adult T Acute Lymphoblastic Leukemia	1
Ann Arbor Stage II Adult Lymphoblastic Lymphoma	1
Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	1
Ann Arbor Stage III Adult Lymphoblastic Lymphoma	1
Bilateral Retinoblastoma	1
Childhood Intraocular Retinoblastoma	1
Group D Retinoblastoma	1
Stage I Retinoblastoma	1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	1
Recurrent Acute Leukemia of Ambiguous Lineage	1
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage	1
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged	1
Ewing Sarcoma	1
Osteosarcoma	1
Pleuropulmonary Blastoma	1
Ann Arbor Stage IIB Hodgkin Lymphoma	1
Ann Arbor Stage IIIB Hodgkin Lymphoma	1
Ann Arbor Stage IVA Hodgkin Lymphoma	1
Ann Arbor Stage IVB Hodgkin Lymphoma	1
Stage I Mixed Cell Type Kidney Wilms Tumor	1
Stage II Mixed Cell Type Kidney Wilms Tumor	1
Stage III Mixed Cell Type Kidney Wilms Tumor	1
Stage IV Mixed Cell Type Kidney Wilms Tumor	1
Acute Lymphoblastic Leukemia, in Relapse	1
Acute Lymphoblastic Leukemia With Failed Remission	1
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Double-Expressor Lymphoma	1
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Recurrent Adult Lymphoblastic Lymphoma	1
Recurrent T Acute Lymphoblastic Leukemia	1
Grade 1 Follicular Lymphoma	1
Grade 2 Follicular Lymphoma	1
Grade 3a Follicular Lymphoma	1
Recurrent Follicular Lymphoma	1
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma	1
Childhood Cancer	1
Primary Central Nervous System Lymphoma	1
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive	1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	1
B Lymphoblastic Leukemia	1
Hematologic Malignancy	1
AML	1
ALL	1
BPDCN	1
Acute Lymphoblastic Lymphoma	1
ALL, Childhood	1
Lymphoblastic Leukemia, Acute, Childhood	1
Refractory B Acute Lymphoblastic Leukemia	1
Refractory B Lymphoblastic Lymphoma	1
Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma	1
Diffuse Large B-Cell Lymphoma Activated B-Cell Type	1
Classical Hodgkins Lymphoma in Children and Adolescents.	1
Cardiotoxicity	1
Children	1
Retinal Neoplasm	1
Previously Untreated Peripheral T-Cell Lymphoma	1

By country register

Register	Trials	Recruiting
Clinical trials in Canada	48	20
Clinical trials in Australia	44	21
Clinical trials in Israel	43	20
Clinical trials in China	39	22
Clinical trials in France	31	11
Clinical trials in Mexico	30	9
Clinical trials in Spain	25	11
Clinical trials in Italy	24	11
Clinical trials in Germany	22	9
Clinical trials in Austria	19	8
Clinical trials in USA	19	6
Clinical trials in Poland	18	6
Clinical trials in Czechia	18	8
Clinical trials in Belgium	17	8
Clinical trials in Netherlands	17	7
Clinical trials in South Korea	16	7
Clinical trials in Taiwan	16	6
Clinical trials in Turkey	13	6
Clinical trials in Japan	13	3
Clinical trials in Brazil	13	5
Clinical trials in Denmark	12	7
Clinical trials in UK	12	4
Clinical trials in Switzerland	11	7
Clinical trials in Sweden	9	4
Clinical trials in Portugal	9	3
Clinical trials in Ireland	7	5
Clinical trials in Norway	7	4
Clinical trials in Singapore	5	3
Clinical trials in India	4	2
Clinical trials in Egypt	2	1
EU register (CTIS)	5	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Vincristine trials

How many clinical trials are testing Vincristine?

121 current trials in our Canada, Australia, Israel, China, France, Mexico, Spain, Italy, Germany, Austria, USA, Poland, Czechia, Belgium, Netherlands, South Korea, Taiwan, Turkey, Japan, Brazil, Denmark, UK, Switzerland, Sweden, Portugal, Ireland, Norway, Singapore, India and Egypt registers name Vincristine (also registered as L01CA02) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Vincristine trials recruiting patients?

Yes. 55 of the 121 trials are recruiting: 20 with sites in Canada, 21 with sites in Australia, 20 with sites in Israel, 22 with sites in China, 11 with sites in France, 9 with sites in Mexico, 11 with sites in Spain, 11 with sites in Italy, 9 with sites in Germany, 8 with sites in Austria, 6 with sites in USA, 6 with sites in Poland, 8 with sites in Czechia, 8 with sites in Belgium, 7 with sites in Netherlands, 7 with sites in South Korea, 6 with sites in Taiwan, 6 with sites in Turkey, 3 with sites in Japan, 5 with sites in Brazil, 7 with sites in Denmark, 4 with sites in UK, 7 with sites in Switzerland, 4 with sites in Sweden, 3 with sites in Portugal, 5 with sites in Ireland, 4 with sites in Norway, 3 with sites in Singapore, 2 with sites in India and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Vincristine clinical trials?

National Cancer Institute (NCI) (20), Children's Oncology Group (16), Institute of Hematology & Blood Diseases Hospital, China (7) and Celgene (4), among 58 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Vincristine clinical trials in Ireland?

Yes. 7 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Vincristine licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Vincristine, for example Vincristine Sulfate 1mg/ml Solution for Injection or Infusion (Pfizer Healthcare Ireland Unlimited Company). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Vincristine shortage?

Not in the lists we track: Vincristine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Vincristine works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vincristine works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vincristine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.